Low dose liposomal amphotericin B seems to be effective against visceral leishmaniasis

BMJ ◽  
2001 ◽  
Vol 323 (7310) ◽  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Low Dose ◽  
Liposomal Amphotericin B

Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal amphotericin B

Open Medicine ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. 305-309
Author(s):  
Sarah Georgiadou ◽  
Dimitrios Kontoyiannis ◽  
Nikolaos Sipsas
Keyword(s):  
Renal Function ◽  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Low Dose ◽  
Parasite Load ◽  
Liposomal Amphotericin B ◽  
Tumor Lysis ◽  
Electrolyte Disturbances ◽  
High Parasite

AbstractWe retrospectively evaluated the rate of renal dysfunction during treatment with liposomal amphotericin B (L-AmB) (3–4 mg/kg, for 7–10 days) in nine consecutive patients with visceral leishmaniasis (VL). During the first week of treatment, 5 patients (56%) experienced transient deterioration of renal function, with a rise in serum creatinine to 1.27–2.44 times the baseline level, and a parallel elevation of uric acid levels without other metabolic or electrolyte disturbances. Serum renal function parameters were restored to normal levels after the completion of therapy, on day 21. These 5 patients had presented with prolonged fever and/or significant spleen enlargement, reflecting high parasite load. This observation suggests that treatment of VL with intermittent L-AmB causes a subclinical tumor lysis-like syndrome, especially in patients with high parasite load.

scholarly journals Sequential Chemoimmunotherapy of Experimental Visceral Leishmaniasis Using a Single Low Dose of Liposomal Amphotericin B and a Novel DNA Vaccine Candidate

2015 ◽  
Vol 59 (9) ◽  
pp. 5819-5823 ◽  
Author(s):  
Karin Seifert ◽  
Christiane Juhls ◽  
Francisco J. Salguero ◽  
Simon L. Croft
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Dna Vaccine ◽  
Liposomal Amphotericin ◽  
Low Dose ◽  
Vaccine Candidate ◽  
Cell Epitope ◽  
Liposomal Amphotericin B ◽  
Antileishmanial Drug ◽  
Suboptimal Dose

ABSTRACTCombination therapies for leishmaniasis, including drugs and immunomodulators, are one approach to shorten treatment courses and to improve the treatment of complex manifestations of the disease. We evaluated a novel T-cell-epitope-enriched DNA vaccine candidate (LEISHDNAVAX) as host-directed immunotherapy in combination with a standard antileishmanial drug in experimental visceral leishmaniasis. Here we show that the DNA vaccine candidate can boost the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice.

Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol

2019 ◽  
Vol 72 ◽  
pp. 101934 ◽  
Author(s):  
Mahmoud Khodabandeh ◽  
Ali Rostami ◽  
Katayoun Borhani ◽  
H. Ray Gamble ◽  
Mohsen Mohammadi
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Interferon Gamma ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B

Treatment of visceral leishmaniasis in children with liposomal amphotericin B

1997 ◽  
Vol 131 (2) ◽  
pp. 271-277 ◽  
Author(s):  
Lucio di Martino ◽  
Robert N. Davidson ◽  
Raffella Giacchino ◽  
Silvestro Scotti ◽  
Francesco Raimondi ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B
Sign in / Sign up

Export Citation Format

Share Document